Naxitamab targets GD2 on tumor cells and kills them via NK cell–mediated ADCC and C1q-initiated complement-dependent cytotoxicity. C1q is an effector component, not the antigen bound by the drug, so C1q-expressing cells are not directly targeted or killed.